AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

📰 Latest breakthroughs
🗺️ Disease Atlas · Endocrine system disorder

ovarian cancer

A primary or metastatic malignant neoplasm involving the ovary. Most primary malignant ovarian neoplasms are either carcinomas (serous, mucinous, or endometrioid adenocarcinomas) or malignant germ cell tumors. Metastatic malignant neoplasms to the ovary include carcinomas, lymphomas, and melanomas.

🔔 Follow weekly
🧬15834genes / proteins with evidence
💊567drugs and clinical candidates
🧪12+recruiting trials worldwide
✅17approved
📈1filed for approval
🧬

Understand ovarian cancer

Cancer · Cells that grow out of control
🎓 Learn more

What it is

Cancer is a disease in which abnormal cells in the body grow out of control and form a tumor. Ovarian cancer is a cancerous tumor that forms in the tissues of an ovary. The ovaries are a pair of female reproductive glands that make eggs and female hormones.

What are the types of ovarian cancer?

There are a few different types of ovarian cancer. The most common type is epithelial cancer. It begins in the cells that cover the ovary.

From MedlinePlus: Ovarian Cancer (US National Library of Medicine) ↗

🧬 Cancer: Cancer is a group of diseases in which some of the body's cells grow and divide without control, and can spread to other parts of the body.

❓ Why it happens

  • Changes (mutations) build up in the genes that tell a cell when to grow, divide and die.
  • Most of these changes happen during life: tobacco, too much sun, alcohol, some infections (such as HPV and hepatitis B and C), radiation, obesity and ageing all raise the risk.
  • Some people inherit a faulty gene that raises their risk, such as BRCA1 or BRCA2.

🫀 What it does to the body

  • Cancer cells form a lump (tumour) that can press on or invade nearby organs.
  • They can travel through the blood or lymph to start new tumours elsewhere (metastasis).
  • Blood cancers crowd out healthy blood cells in the bone marrow.

🧱 Why it is hard to cure

  • Every cancer is different, even between two people with the same type - and inside one tumour.
  • Cancer cells keep changing, so they can learn to resist a medicine that worked at first.
  • Cancer cells are the body's own cells, so killing them without harming healthy cells is hard.
  • Many cancers cause no symptoms until they have spread, and a new medicine often takes more than ten years to go from the lab to patients.

🚀 What research is trying now

  • Targeted medicines against the exact gene change in a tumour (for example EGFR, ALK or KRAS).
  • Immunotherapy that helps the immune system recognise cancer, including CAR-T cell therapy.
  • Personalised cancer vaccines built from each tumour's mutations, now in late trials.
  • Blood tests that look for tumour DNA to find cancer earlier, and AI to read scans and slides.

General information about cancer, reviewed by people; it does not describe any one person. Below: the evidence for ovarian cancer itself.

🤖

AI briefing

Where the science on ovarian cancer stands, from the evidence on this page

AI reads the targets, drugs, trials and papers below and writes where the science stands — every claim cited. It is shared with everyone who opens ovarian cancer.

🎯

Top targets

Genes and proteins ranked by Open Targets evidence (0-1)
BRCA1 BRCA1 DNA repair associatedPROTACantibodysmall molecule🧊 AlphaFold structure ↗ 0.90
BRCA2 BRCA2 DNA repair associatedPROTACsmall molecule🧊 AlphaFold structure ↗ 0.89
RAD51C RAD51 paralog CPROTACsmall molecule🧊 AlphaFold structure ↗ 0.83
TP53 tumor protein p53PROTACothersmall molecule🧊 AlphaFold structure ↗ 0.81
RAD51D RAD51 paralog DPROTACsmall molecule🧊 AlphaFold structure ↗ 0.80
BRIP1 BRCA1 interacting DNA helicase 1PROTAC🧊 AlphaFold structure ↗ 0.79
PIK3CA phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alphaPROTACantibodysmall molecule🧊 AlphaFold structure ↗ 0.79
PALB2 partner and localizer of BRCA2PROTACsmall molecule🧊 AlphaFold structure ↗ 0.77
PTEN phosphatase and tensin homologPROTACantibodysmall molecule🧊 AlphaFold structure ↗ 0.76
MSH6 mutS homolog 6PROTACsmall molecule🧊 AlphaFold structure ↗ 0.76
POLE DNA polymerase epsilon, catalytic subunitPROTACantibodysmall molecule🧊 AlphaFold structure ↗ 0.75
MSH2 mutS homolog 2PROTACsmall molecule🧊 AlphaFold structure ↗ 0.74
CHEK2 checkpoint kinase 2PROTACsmall molecule🧊 AlphaFold structure ↗ 0.73
CDH1 cadherin 1PROTACantibodysmall molecule🧊 AlphaFold structure ↗ 0.72
MLH1 mutL homolog 1PROTACsmall molecule🧊 AlphaFold structure ↗ 0.72

Green labels: what the target is known to be druggable by. The score combines genetics, somatic mutations, drugs, expression and literature.

💊

Drugs and candidates

Every medicine linked to ovarian cancer, by how far it has got
Approved · 17
AltretamineApproved
AmifostineApproved
CarboplatinApproved
Doxorubicin HydrochlorideDNA topoisomerase II alpha inhibitorApproved
Gemcitabine HydrochlorideRibonucleoside-diphosphate reductase RR1 inhibitor; DNA polymerase (alpha/delta/epsilon) …Approved
Influenza Virus VaccineApproved
Show all 17
Ku-0058948Approved
MelphalanApproved
MibefradilVoltage-gated T-type calcium channel blockerApproved
Mirvetuximab SoravtansineFolate receptor alpha binding agent; Tubulin inhibitorApproved
NiraparibPoly [ADP-ribose] polymerase 2 inhibitor; Poly [ADP-ribose] polymerase-1 inhibitorApproved
Niraparib Tosylate MonohydratePoly [ADP-ribose] polymerase 2 inhibitor; Poly [ADP-ribose] polymerase-1 inhibitorApproved
OlaparibPARP 1, 2 and 3 inhibitorApproved
RucaparibPARP 1, 2 and 3 inhibitorApproved
Rucaparib CamsylatePARP 1, 2 and 3 inhibitorApproved
TopotecanDNA topoisomerase I inhibitorApproved
Topotecan HydrochlorideDNA topoisomerase I inhibitorApproved
In phase 2 / 3 · 20
BevacizumabVascular endothelial growth factor A inhibitorFiled for approval
AlvimopanMu opioid receptor antagonistPhase 3
AmonafidePhase 3
AtezolizumabProgrammed cell death 1 ligand 1 inhibitorPhase 3
AvelumabProgrammed cell death 1 ligand 1 otherPhase 3
AzenosertibSerine/threonine-protein kinase WEE1 inhibitorPhase 3
Show all 20
BatiraxceptGrowth arrest-specific protein 6 inhibitorPhase 3
BenmelstobartPhase 3
CadonilimabProgrammed cell death protein 1 inhibitor; Cytotoxic T-lymphocyte protein 4 inhibitorPhase 3
CanfosfamidePhase 3
Canfosfamide HydrochloridePhase 3
Catequentinib HydrochloridePhase 3
CediranibStem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor inhib…Phase 3
CisplatinPhase 3
CyclophosphamidePhase 3
DostarlimabProgrammed cell death protein 1 antagonistPhase 3
DoxorubicinDNA topoisomerase II alpha inhibitorPhase 3
DurvalumabProgrammed cell death 1 ligand 1 inhibitorPhase 3
Epoetin AlfaErythropoietin receptor agonistPhase 3
EtarfolatidePhase 3
Early trials · 20
Arsenic TrioxideThioredoxin reductase 1 inhibitorPhase 1/2
Astx-660Phase 1/2
Azd-8797Phase 1/2
Azd-9574Phase 1/2
BelinostatHistone deacetylase inhibitorPhase 1/2
BexmarilimabPhase 1/2
Show all 20
Bms-986148Phase 1/2
Bmx-001Phase 1/2
Bnc-105PPhase 1/2
Bt-5528Phase 1/2
CamizestrantEstrogen receptor alpha degraderPhase 1/2
Carfilzomib26S proteasome inhibitorPhase 1/2
CobimetinibDual specificity mitogen-activated protein kinase kinase 1 inhibitor; Dual specificity mi…Phase 1/2
Com-701Phase 1/2
ConatumumabTumor necrosis factor receptor superfamily member 10B agonistPhase 1/2
Cp-506Phase 1/2
Ct-7001Phase 1/2
Cyc-065Phase 1/2
Deoxycholic AcidPhase 1/2
DianhydrogalactitolPhase 1/2
🧪

Recruiting trials

Worldwide, open to new patients now
ChemoINTEL Assay Algorithm Development Study: In-Vitro Cytotoxic Drug Induced Apoptosis Correlation with Pati…NCT06844136 · n/a · 📍 LiverpoolIdentification of Genetic, Phenotypic, Clinical, Biological and Histological Factors Differentiating Patients…NCT07361471 · NA · 📍 Clermont-FerrandRepurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian CancerNCT05998135 · Phase 2 · 📍 AtlantaSetting Up ctDNA Analysis on Archived Plasma SamplesNCT07546578 · n/a · 📍 RomaMIRRORS-FROZEN - Comparing Open Vs Robotic Surgery in the Management of Women with Complex Pelvic Adnexal Mas…NCT06638593 · NA · 📍 GuildfordGB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube CancerNCT07489287 · Phase 1 · 📍 BuffaloCombination Therapy for Recurrent Ovarian CancerNCT05610735 · Phase 1, Phase 2 · 📍 LouisvilleMUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian CancerNCT06483048 · Phase 1 · 📍 ScottsdaleTrop2-targeted immunoPET Imaging of Solid TumorsNCT06851663 · Phase 2, Phase 3 · 📍 ShanghaiStudy on the Dynamic Changes of Metabolic Biomarkers and Their Prognostic Relationship in Ovarian CancerNCT06019923 · n/a · 📍 HangzhouThe Efficacy and Safety of FRD001 in Ultrasound Contrast Imaging for Malignant Ovarian Masses in WomenNCT06556342 · NA · 📍 WuhanRoutine Shallow-coverage Whole Genome Sequencing Testing of Liquid-based Cervical Smears for the Early Diagno…NCT07821879 · n/a · 📍 Toulouse Search more trials →
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy